Fig. 1From: SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckOverall survival (OS) by PD-L1 expressiona. aPatients with PD-L1 result n = 396: a TC ≥ 25%, b TC ≥ 10%, and c TC ≥ 50%; d oropharynx anatomical sub-site (n = 91) by PD-L1 statusBack to article page